MedTrace Logo

Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib

NCT06545110 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2024-08-09

No results posted yet for this study

Summary

Assess serum and tissue retinol binding protein 4 in patients with severe alopecia areata in correlation with healthy individuals .

Estimate genetic profile of retinol binding protein4 in severe alopecia areata patients

Assess possible role of retinol binding protein 4 genetic mutation in response to barcitinib treatment in patients with severe alopecia areata .

Conditions

Interventions

DRUG

Baricitinib Oral Tablet

Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Mostafa Adam Ali El Tieb, professor · Aswan University

  • Mohamed Hosny Hassan, professor · South Valley University

  • Eisa Mohammed Hegazy, professor · South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-09-30
Completion
2024-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06545110 on ClinicalTrials.gov